Maria M. Silaenkova

Maria M. Silaenkova

Auto-generated profile, based on publicly available information

Maria M. Silaenkova

National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2024 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
IFI. E. Filatov
I. E. Filatov
MSM. M. Silaenkova
M. M. Silaenkova
VTV. V. Tsibezov
V. V. Tsibezov
MBM. V. Balandina
M. V. Balandina
SNS. N. Norkina
S. N. Norkina
Tatiana Vladimirovna GrebennikovaTatiana Vladimirovna Grebennikova
Tatiana Vladimirovna Grebennikova
INTRODUCTION. Rotavirus vaccines based on virus-like particles (VLPs), non-infectious recombinant proteins of human rotavirus A that mimic the structure of the native virus, show promise for preventive vaccination. Presumably, the optimal method to determine the potency of VLP-based rotavirus vaccines is the enzyme-linked immunosorbent assay (ELISA) method used to measure the titre of specific IgG antibodies to rotavirus A proteins in serum samples from vaccinated animals.AIM. This study aimed at assessing the potency of a VLP-based rotavirus vaccine by developing and validating an analytical procedure using ELISA to determine the levels of antibodies to the VP2 and VP6 proteins of rotavirus A in serum samples from vaccinated guinea pigs.MATERIALS AND METHODS. The potency of the VLP-based rotavirus vaccine was determined in vivo in three types of experimental animals, including BALB/c mice, agouti guinea pigs, and newborn minipigs. The animals received three intramuscular injections of the vaccine at a dose of 30 µg. This study used the indirect ELISA method to quantify VP2- and VP6-specific immunoglobulin G (IgG) antibodies and the virus-neutralisation test to measure neutralising antibodies (nAbs) to rotavirus A in animal serum samples. The study involved calculating the geometric mean titres (GMTs) of antibodies. The authors validated the analytical procedure for potency assessment on two batches of the vaccine using standard statistical analysis methods.RESULTS. The study compared VP2- and VP6-specific IgG and nAb levels 14 days after the first, second, and third vaccinations. The authors observed a significant increase in antibody titres and statistically significant (p<0.05) differences between groups as early as after the second vaccination. Double vaccination induced rotavirus-specific IgGs and nAbs in newborn minipigs (GMTs of 200.0 and 108.9, respectively) and guinea pigs (GMTs of 12,800 and 2,600, respectively). Vaccinated mice demonstrated a significant increase in rotavirus-specific IgG levels (GMT of 572,440). Guinea pigs were selected as a relevant model for validating the ELISA-based potency assessment procedure. The validation study used a double vaccination scheme. The validation using two batches of the VLP-based rotavirus vaccine indicated that the ELISA-based analytical procedure met the acceptance criteria for specificity, repeatability, and intermediate precision. The repeatability assessment resulted in a coefficient of variation (CV) of 12.4% for batch 1 and a CV of 7.7% for batch 2, whereas the intermediate precision assessment showed a CV of 6.9% for batch 1 and a CV of 10.2% for batch 2, which were within the acceptance criteria for both validation parameters (CV≤15%).CONCLUSIONS. The authors developed and validated an ELISA-based analytical procedure for assessing the potency of VLP-based preventive rotavirus vaccines. According to the study results, ELISA is applicable to the control of the potency of VLP-based preventive rotavirus vaccines.

15 April 2026 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
Oleg Vladimirovich LedenevOleg Vladimirovich Ledenev
Oleg Vladimirovich Ledenev
LKLudmila V. Kostina
Ludmila V. Kostina
OEOlesya V. Eliseeva
Olesya V. Eliseeva
OLOleg E. Latyshev
Oleg E. Latyshev
MSMaria M. Silaenkova
Maria M. Silaenkova
Tatiana Vladimirovna GrebennikovaTatiana Vladimirovna Grebennikova
Tatiana Vladimirovna Grebennikova
Background. Rotavirus infection remains a major cause of severe gastroenteritis in children worldwide. Virus-like particle (VLP)-based vaccines are considered a promising non-replicating alternative to live vaccines due to their favorable safety profile. Objective. To evaluate the acute toxicity of the VLP-based vaccine “Gam-VLP-rota” following single intramuscular administration in Sprague–Dawley (SD) rats. Materials and Methods. Male and female SD rats were allocated into four experimental groups (vehicle control; 30, 120, and 600 µg antigen per animal; n = 14 per sex per group). The vaccine was administered once into the quadriceps femoris muscle (0.2 mL per animal). Animals were euthanized either 24 h after administration (Day 2) or after a 14-day recovery period (Day 15). Clinical condition, body weight, and food consumption were monitored. Hemostasis parameters, hematology, serum biochemistry, bone marrow cellular composition, organ weights, necropsy findings, histopathology, and local tolerability were evaluated. Results. No mortality or severe clinical manifestations were observed. On Day 2, transient intergroup differences in body weight gain and moderate reduction in food intake were detected in animals receiving the highest antigen dose (600 µg). These parameters normalized by Days 7–15. Reversible changes in hemostasis were recorded, including prolonged prothrombin time and elevated fibrinogen levels. Hematological analysis on Day 2 demonstrated dose-dependent neutrophilia accompanied by relative lymphopenia with absolute lymphocytosis; hematological and myelogram parameters returned to baseline by Day 15. In serum biochemistry, animals receiving 600 µg antigen showed increased total protein and globulin levels in both sexes, along with decreased ALT and alkaline phosphatase activity in males; these differences resolved by Day 15. No pathological alterations were detected macroscopically or microscopically in examined organs. Reactive enlargement of inguinal lymph nodes without signs of inflammation was observed. No local irritative effects were identified. Conclusion. Single intramuscular administration of the VLP-based vaccine “Gam-VLP-rota” at a dose of 600 µg antigen per animal (approximately 20× the anticipated clinical dose) demonstrated a favorable safety profile in an acute toxicity model. Keywords: rotavirus; virus-like particles; preclinical toxicology; hematology; serum biochemistry; histopathology; Sprague–Dawley rats; vaccine safety.

7 November 2026 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
MSMaria M. Silaenkova
Maria M. Silaenkova
Oleg Vladimirovich LedenevOleg Vladimirovich Ledenev
Oleg Vladimirovich Ledenev
LKLudmila V. Kostina
Ludmila V. Kostina
OEOlesya V. Eliseeva
Olesya V. Eliseeva
AMArkady N. Murashev
Arkady N. Murashev
TGTatyana V. Grebennikova
Tatyana V. Grebennikova
Objective: This study evaluated the potential immunotoxicity and safety of a novel hexavalent virus-like particle (VLP)-based rotavirus vaccine candidate by assessing the t-cell-dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) in Sprague-Dawley (SD) rats. Methods: SD rats (24 males, 24 females) received three intramuscular vaccine injections at antigen doses of 30, 120, or 600 µg at 14 d intervals, followed by two KLH immunizations (on d 29 and d 35). Safety was monitored via clinical signs, body weight, food consumption, gross pathology, organ weight, and plasma KLH-specific immunoglobulin M (KLH-IgM) and immunoglobulin G (KLH-IgG) levels measured by enzyme-linked immunosorbent assay (ELISA) on d 35, d 42, and d 49. Results: Repeated-dose administration of the "Gam-VLP-rota" vaccine was tolerated, causing no mortality, adverse clinical signs, gross tissue pathology, or systemic organ toxicity. Absolute body weight and food intake remained within physiological norms. Comprehensive gravimetric analysis of internal organs revealed no adverse effects on the metabolic, reproductive, or central nervous systems in either sex. One-way ANOVA followed by Dunnett’s post-hoc test demonstrated that female organ weights remained stable, whereas male rats at the 600 μg dose exhibited a localized enlargement of the thymus (p<0.05). To systematically control type I error inflation across multi-dose longitudinal body weight data, post-hoc pairwise comparisons were subjected to Benjamini–Hochberg FDR adjustments, under which somatic variations did not exceed critical thresholds (adjusted q ≥ 0.3195). However, two-way ANOVA on log-transformed datasets revealed highly significant sex ⨯ treatment interactions for KLH-IgG on d 35 (p = 0.007) and KLH-IgM on d 49 (p = 0.028). Within-sex post-hoc testing with Bonferroni correction revealed a dose-dependent humoral response in females: on d 49, all vaccine groups (30, 120, and 600 µg) significantly exceeded the vehicle control group for KLH-IgM (padj ≤ 0.0125), validated by a monotonic Jonckheere–Terpstra trend test (p = 0.00097). Conclusion: The hexavalent VLP-based vaccine was well-tolerated with no overt immunosuppression or systemic toxicity observed. However, the toxicological significance of the observed thymus enlargement and antibody fluctuations requires further investigation.

15 June 2026 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
MSMaria M. Silaenkova
Maria M. Silaenkova
TGTIMUR GARAEV
TIMUR GARAEV
IYIlya Yudin
Ilya Yudin
Oleg Vladimirovich LedenevOleg Vladimirovich Ledenev
Oleg Vladimirovich Ledenev
OEOlesya V. Eliseeva
Olesya V. Eliseeva
Tatiana Vladimirovna GrebennikovaTatiana Vladimirovna Grebennikova
Tatiana Vladimirovna Grebennikova
Objective: This study aimed to develop and evaluate stable pharmaceutical compositions based on squalene derived from both animal (shark liver) and plant (amaranth oil) sources. Methods: Oil-in-water nanoemulsions were prepared and stored at 4 °C for six months to evaluate stability. Key stability parameters, including droplet size and zeta potential, were determined using Dynamic Light Scattering (DLS). The immunogenicity of VLP-based rotavirus vaccine formulations containing these adjuvants was evaluated in a guinea pig model. Humoral and cellular immune responses were quantified using Enzyme-Linked Immunosorbent Assay (ELISA) for IgG titers, Neutralization Assays (NA) for virus-neutralizing activity, and the Lymphocyte Blast Transformation Reaction (LBTR) to assess cell-mediated immunity. Results: Both formulations exhibited high stability at 4 °C. Mean droplet diameters were 157 ± 3 nm (animal-derived) and 149 ± 3 nm (plant-derived), which were smaller than the commercial reference (174 ± 4 nm). Zeta potential values (-35 to -39 mV) confirmed robust colloidal stability. Immunization elicited potent responses; no statistically significant differences were observed between the two squalene sources regarding specific IgG titers (GM = 126 267) or virus-neutralizing activity (VNA GM = 640 vs 452.5, p > 0.05). Cellular immunity was induced by both adjuvants, yielding Proliferation Stimulation Index (PSI) values of 3.11 for the plant-derived formulation and 2.10 for the animal-derived variant. Conclusion: Plant-derived squalene from amaranth oil is a highly effective, sustainable alternative to shark-derived components, providing comparable stability and immunogenic potency for vaccine delivery. Keywords: pharmaceutical compositions, adjuvants, squalene, amaranth oil, nanoemulsions, virus-like particles, VLPs, vaccine formulations.